Optimizing Frontline Treatment for PTCL
-
Published:2024-09
Issue:
Volume:24
Page:S108-S110
-
ISSN:2152-2650
-
Container-title:Clinical Lymphoma Myeloma and Leukemia
-
language:en
-
Short-container-title:Clinical Lymphoma Myeloma and Leukemia
Reference18 articles.
1. Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T. cell lymphoma;Heavican;Blood,2019
2. Real-world data on prognostic factors and treatment in peripheral T. cell lymphomas: a study from the Swedish Lymphoma Registry;Ellin;Blood,2014
3. A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial;Advani;Br J Haematol,2016
4. Final results of a phase II study of CHOEP plus lenalidomide as initial therapy for patients with stage II-IV peripheral T-cell lymphoma;Stuver;Br J Haematol,2023
5. Romidepsin Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Versus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Final Analysis of the Ro-CHOP Trial;Camus;J Clin Oncol,2024